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Over the past three decades the
pharmacotherapy of asthma has
been based on glucocorticoids, ß2
agonists and theophyllines.
Research conducted over the past
10 years has led to greater
understanding of the cellular and
molecular basis of asthma,
particularly the role of the
underlying inflammatory process.
Both national and international
guidelines stress the importance of
switching off the inflammatory cascade
(Figure 1).  Glucocorticoids are the
most effective anti-inflammatory
agents available and in many countries,
including Malta, they are used as first
line treatment.  However, despite their
proven safety and efficacy, there are
still a number of patients whose asthma
is not adequately controlled and as a
consequence have a poor quality of life.
The search for alternative
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pharmacological agents that target
airway inflammation and ease the
problem of compliance has led to a
novel class of non-steroidal anti-asthma
drugs which are effective over a wide
range of asthma severity, have a high
therapeutic index, are orally active and
have a once daily or twice daily
regimen.  Leukotriene receptor
antagonists are a hybrid between a
preventer of inflammation (antagonism
of inflammatory activities of
leukotrienes) and bronchodilating
reliever (antagonism of leukotriene
induced smooth muscle
bronchoconstriction).  Currently
available on the local market is
zafirlukast (Accolate®, Zeneca) which is
a cysteinyl leukotriene antagonist.
Another drug within this class, however
not as yet available locally, is
montelukast (Singulair®, Merck).
What are leukotrienes?
Leukotrienes are a group of
arachidonic acid derivatives that are
produced during asthmatic reactions by
cells involved in the pathogenesis of
asthma and other inflammatory
diseases.  The cysteinyl leukotrienes C
4
(LTC
4
), D
4
 (LTD
4
) and E
4
 (LTE
4
) are
important mediators of inflammation.
They are formed in many cells including
mast cells and eosinophils and are
potent inducers of bronchoconstriction,
plasma exudation and mucus
production.
How do the new anti-
leukotriene drugs work?
There are currently four classes of
anti-asthma and anti-inflammatory
drugs which interfere with leukotriene
synthesis or activity which are under
development as seen in Figure 2.  These
are 5-lipoxygenase inhibitors and 5-
lipoxygenase activating protein (FLAP)
inhibitors which block the synthesis of
cysteinyl leukotrienes and the
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Figure 1   The inflammatory cascade in asthma
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leukotriene B
4
 (LTB
4
).  The third class
are competitive antagonists of LTB
4
.
The drugs which are currently available
in Malta and the UK are those of the
4th class and act by competitively
blocking the activity of cysteinyl
leukotrienes at the LTD
4
 receptor.  They
are termed cysteinyl leukotriene
receptor antagonists.
When should leukotriene
receptor antagonists be used?
The local guidelines on the
management of asthma issued by the
Malta Lung Study Group do not mention
the use of leukotriene receptor
antagonists.  However, these guidelines
are in the process of being revised.  The
position of these drugs in the
international guidelines is still unclear
due to the lack of published data at the
time of drawing up these guidelines.  It
is debatable whether these drugs
should be used as first-line preventive
monotherapy instead of low dose
inhaled corticosteroids in patients with
mild persistent asthma or as an
alternative to long-acting
bronchodilators, i.e. second-line
therapy, in addition to inhaled
corticosteroids in patients with
moderate to severe persistent asthma.
It is important to note that
leukotriene receptor antagonists should
be taken on a regular basis to achieve
benefit, even during symptom free
periods and should normally be
continued during acute exacerbations
of asthma.  However, they are not
indicted to relieve an attack of acute
severe asthma.
In the UK, zafirlukast is licensed for
use in patients aged 12 years and over.
It may be used as first line therapy
instead of inhaled corticosteroids in
mild persistent asthma.  Montelukast is
licensed in patients aged 6 and over as
second line asthma treatment in
combination with inhaled
corticosteroids and as monotherapy in
exercise induced asthma.
Clinical considerations
Zafirlukast and montelukast both
achieve peak plasma concentrations
approximately 3 hours after oral
administration.  There is a 40%
decrease in the bioavailability of
zafirlukast when taken with food; it is
therefore recommended that the tablets
should not be taken with food as this
could lead to a decreased
pharmacological response.  Co-
adminstration of zafirlukast with
erythromycin, theophylline or
terfenadine results in a decrease in the
plasma concentration of zafirlukast,
while an increase results when it is co-
administered with aspirin.  In smokers
the clearance of zafirlukast may be
increased by about 20%.  Prescribing
information regarding the use of
zafirlukast states that the safety of this
drug in pregnancy has not been
established and since it is excreted in
breast milk it should not be
administered to lactating mothers.
Official montelukast prescribing
information advises that the use of
montelukast is avoided in pregnancy
and lactation unless essential.
Conclusion
Leukotriene receptor antagonists
represent an important advance in
asthma therapy.  They are active over a
wide range of asthma severity and have
both an anti-inflammatory and a
bronchodilator property.  They are
active orally, therefore overcoming the
potential problems with compliance
when using inhalers.
They also act within the first 24
hours while inhaled corticosteroids take
a much longer time to achieve maximal
The literature suggests that leukotriene
receptor antagonists may be of particular use in:
• exercise induced asthma
• asthmatics who are intolerant to aspirin and other non-steroidal
anti- inflammatory drugs
• nocturnal asthma
• asthmatics who concomitantly present with allergic rhinitis.
Figure 2 The four groups of anti-asthma and anti-inflammatory drugs
directed against LT synthesis and activity
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Table 1 Leukotriene Receptor Antagonists
Generic Propriety Oral dose Other information
Zafirlucast Accolate 20 mg bd Take 1hr before or 2hr
(Zeneca) after eating.
Montelukast Singulair Adults: Paediatric dose
(Merck) 10 mg at night available as
chewable
Paed: (6-12yr): tablets.
5 mg at night
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response.  However, when compared to inhaled
beclomethosone 400 micrograms daily both the above
mentioned drugs appear to be less effective in mild to
moderate asthmatics.  They are comparable in cost to long
acting ß
2
 agonists but more expensive than low dose inhaled
steroids.
While further long term studies are required to determine
the position of these drugs in asthma treatment guidelines,
they provide oral, safe and effective therapy. ✱
1. The inflammatory process
in asthma is:
a. of secondary importance
b the main pathological
process in asthma
c the target of all anti-
asthma drugs
d all of the above.
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Assessment
Questions:
2. Which of the following
statements is true?
a. Leukotrienes are
arachidonic acid
derivatives
b. Leukotrienes are only
involved in the
pathogenesis of asthma
c. Leukotrienes are only
produced in mast cells
d. Leukotrienes are not
involved in mucus
production.
Select only ONE option in each question
by ticking the respective box
on the Response Sheet (page 39).
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3. Leukotriene receptor
antagonists are
a. non-steroidal drugs
b. enhance the
inflammatory process
c. steroidal drugs
d a combination of answers
a and b.
4. Leukotriene receptor
antagonists
a. have anti-inflammatory
activities
b. act in the same way as ß
2
agonists
c. have bronchodilating
effects
d. a combination of answers
a and c.
5. Leukotriene receptor
antagonists currently
available on the local
market are
a. pranlukast
b. montelukast
c. zafirlukast
d. salbutamol
6. The cysteinyl leukotriene
receptor antagonists act
by
a reducing arachidonic
production
b. reducing FLAP synthises
c. competing with the LTB4
receptor
d. blocking the LTD4
receptor.
7. Which of the following
statements is true
a. an example of a 5-
lipoxygenase inhibitor is
montelukast
b. LTD4 is a not cysteinyl
leukotriene
c. zafirlukast is a cysteinyl
leukotriene receptor
antagonist
d. cysteinyl leukotriene
receptor antagonists are
ineffective if taken with
inhaled corticosteroids.
12. Which of the following
statements is true?
a. zafirlukast is licensed
only for use in patients
over 12 years of age.
b. zafirlukast is also
licensed for use in
children over 6 years of
age
c. montelukast is of no use
in exercise induced
asthma
d. montelukast has a low
therapeutic index.
13. Zafirlukast and
montelukast achieve peak
plasma concentrations
how long after
administration?
a. after 30 minutes
b. after 1 hour when taken
with food
c. after 3 hours
d. none of the above
14. Zafirlukast is available as
a. an inhaler
b. nebuliser solution
c a tablet
d. a combination of answers
a and b.
15. Montelukast is available
as
a. chewable tablets for
children
b. suspension
c. tablets for adults
d. a combination of answers
a and c.
16. The dosage regimen for
zafirlukast is
a. 20 mg bd. with food
b. 20 mg bd. 2 hours after
food
c. 20 mg bd. 1 hour before
food
d. a combination of answers
b and c
17.The use of cysteinyl
leukotriene receptor
antagonists in pregnancy
and lactation
a. is absolutely safe.
b. is recommended after the
2nd trimester
c. is not recommended
d. none of the above.
18.One of the major
advantages of cysteinyl
leukotriene receptor
antagonists is
a. their low cost
b. that they over come the
problem of compliance
with inhalers
c. that they can safely be
used in children of all
ages
d. that they have no side
effects.
19.When used in mild to
moderate asthma
leukotriene receptor
antagonists
a. are the most effective
anti-inflammatory agents
b. are less effective than
inhaled beclomethosone
400(g daily
c. are just as effective as
any anti-asthma drug
d. are of no use.
20.Which of the following
statements is true?
a. cysteinyl leukotriene
receptor antagonists
should be taken on a prn
basis
b. cysteinyl leukotriene
receptor antagonists
should be taken on a
regular basis
c. cysteinyl leukotriene
receptor antagonists
should only be taken in
conjunction with
salmeterol
d. cysteinyl leukotriene
receptor antagonists
should not be taken if
cough is present.
8. The recommended use of
cysteinyl leukotriene
receptor antagonists
a. as reliever therapy i.e.
instead of short acting (2
agonists
b. instead of oral
prednisolone
c. instead of inhaled
steroids in mild
persistent asthma
d. instead of nebulised
therapy.
9. Zafrilukast is also
licensed for use in
a. COPD
b. bronchitis
c. emphysema
d. none of the above.
10.Leukotriene receptor
antagonists are of
particular use in
a. aspirin sensitive
asthmatics
b. asthmatics allergic to
salbutamol
c. persons presenting with
occupational asthma
d. none of the above.
11.Which of the following
statements is false?
a. cortocosteriods are the
most effective anti-
inflammatory agents
available
b. zafirlukast is the only
cysteinyl leukotriene
receptor antagonist
available locally
c. montelukast is licensed
for use in the UK
d. leukotriene receptor
antagonists only have a
bronchodilating effect.
”To loose one’s health renders science null, art inglorious,
strenght effortless, wealth useless and eloquence powerless.”
Adversus Ethicus
